Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease
transmitted by infected mosquitoes. Malaria remains a major global health challenge …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Malaria is a life‐threatening disease caused by parasites of the P lasmodium genus. In
many parts of the world, the parasites have developed resistance to a number of antimalarial …

Background BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based
on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to …

Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …